Interstitial lung disease is one of the most important causes of mortality in patients with polymyositis or dermatomyositis. Understanding the risk factors for development and progression of interstitial lung disease is crucial to improving clinical outcomes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The prognostic role of C-reactive protein to albumin ratio and anti-MDA5 antibody-positive in idiopathic inflammatory myopathy: a retrospective study
Scientific Reports Open Access 08 March 2023
-
Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients
Orphanet Journal of Rare Diseases Open Access 30 January 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hallowell, R. W., Ascherman, D. P. & Danoff, S. K. Pulmonary manifestations of polymyositis/dermatomyositis. Semin. Respir. Crit. Care Med. 35, 239–248 (2014).
Zhang, L. et al. Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis. PLoS ONE 11, e0155381 (2016).
Fujisawa, T. et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS ONE 9, e98824 (2014).
Hamaguchi, Y. et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multi-centre, cross-sectional study. Arch. Dermatol. 147, 391–398 (2011).
Hamaguchi, Y. et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE 8, e60442 (2013).
Sato, S. et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS ONE 11, e0154285 (2016).
Chen, Z. S. et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. (Hoboken) 65, 1316–1324 (2013).
Kawasumi, H., Gono, T., Kawaguchi, Y. & Yamanaka, H. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin. Med. Insights Circ. Respir. Pulm. Med. 9, 9–17 (2015).
Gono, T. et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 51, 1563–1570 (2012).
Gono, T. et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford) 53, 2196–2203 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.G. declares no competing interests. M.K. is an inventor on US patent application 13/059,444: 'Diagnosis method and diagnosis kit for dermatomyositis'.
Rights and permissions
About this article
Cite this article
Gono, T., Kuwana, M. Choosing the right biomarkers to predict ILD in myositis. Nat Rev Rheumatol 12, 504–506 (2016). https://doi.org/10.1038/nrrheum.2016.120
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2016.120
This article is cited by
-
The prognostic role of C-reactive protein to albumin ratio and anti-MDA5 antibody-positive in idiopathic inflammatory myopathy: a retrospective study
Scientific Reports (2023)
-
Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients
Orphanet Journal of Rare Diseases (2021)
